Actively Recruiting
Evaluating the Safety and Effects of ZL-1310 Alone and With Atezolizumab and Carboplatin in Small Cell Lung Cancer
Led by Zai Lab (Shanghai) Co., Ltd. · Updated on 2026-10-16
339
Participants Needed
41
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug ZL-1310 in people with extensive small cell lung cancer SCLC. This phase 1, open-label study aims to assess the safety, effectiveness, and how the body processes ZL-1310 alone and in combination with other drugs including Atezolizumab and Carboplatin. The study includes participants who have not received prior systemic treatment for SCLC or those with disease progression after chemotherapy. Participants may receive ZL-1310 alone, with Atezolizumab, or with both Atezolizumab and Carboplatin as induction therapy followed by maintenance treatment. The study includes different dosing levels established from earlier dose escalation and multiple arms to explore these combinations. Some participants may receive extended dosing based on emerging data and prior treatments. During the study, participants will undergo tumor biopsies or provide archived tumor tissue. Researchers will monitor safety through adverse event tracking up to 24 months, assess tumor responses using imaging scans, and measure pharmacokinetics of ZL-1310. The study also evaluates disease control rates and progression-free survival. Participation involves regular assessments and treatments over several months with follow-up to monitor outcomes.
CONDITIONS
Brief Title
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Research Team
E
Erin Nurre
M
Mona Qureshi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here